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        During the immune response to for-
eign antigens, B lymphocytes become 
activated and begin to diversify their 
immunoglobulin (Ig) genes to ensure 
the production of diverse, high-affi   nity 
antibodies against pathogens. This pro-
cess involves somatic hypermutation 
(SHM) and class switch recombination 
(CSR), both of which require activa-
tion-induced deaminase (AID), an en-
zyme that deaminates dC to dU in the 
Ig loci. The resulting U:G mismatches 
can be resolved by several pathways in-
volving base excision repair proteins, 
mismatch repair proteins, and low-fi  -
delity DNA polymerases. During SHM, 
mutations are fi  rst introduced into re-
arranged Ig variable genes by AID. The 
spectrum of mutations is then expanded 
from the initial deaminated dC base to 
include neighboring nucleotides by the 
action of the DNA polymerase      dur-
ing error-prone gap repair. Thus, the 
simple deamination of dC to dU pro-
duces a plethora of diff  erent amino acid 
changes within an antibody, which can 
then be selected to bind antigen with 
high affi   nity. Similarly, during CSR, ura-
cil bases are introduced into intronic 
switch regions preceding each of the 
heavy chain constant genes. DNA strand 
breaks in the switch regions are gener-
ated when uracil is removed by uracil 
DNA glycosylase and the abasic site is 
nicked by an endonuclease. The breaks 
are then processed by the nonhomolo-
gous end-joining pathway to recom-
bine variable genes from the      constant 
gene to other constant genes. AID thus 
initiates mutations and strand breaks, a 
potentially catastrophic combination for 
genome stability. To harness its mu-
tagenic activity, AID is extensively reg-
ulated at the level of transcript stability 
(  1, 2  ), protein expression (  3, 4  ), subcel-
lular localization (  5, 6  ), phosphoryla-
tion (  7  ), and degradation (  8  ). On page   99   
of this issue, Pauklin et al. fi  nd that 
AID is activated by the sex hormone 
estrogen, revealing yet another level of 
AID regulation (  9  ).   
  Estrogen regulation of AID 
  Estrogen functions as a transcriptional 
regulator by activating estrogen re-
ceptors, which then translocate to the 
nucleus, where they bind to estrogen 
response elements in gene promoters. 
Pauklin et al. found functional binding 
sites for estrogen receptors in the pro-
moter region of the AID gene, based 
on electromobility shift and chromatin 
immunoprecipitation assays (  9  ). Treat-
ing B cells with estrogen caused higher 
AID transcript and protein levels, and 
conversely, treating the cells with pro-
gesterone suppressed transcription of 
AID. The authors found that estrogen-
induced activation of AID triggered 
modest increases in SHM and CSR, 
and increased the frequency of   Myc-
IgH   translocations. Perhaps the most 
profound result of the study was the 
identifi  cation of AID transcripts in breast 
and ovarian tissues, which argues against 
the dogma that AID is only expressed 
in B cells. Thus, in tissues where es-
trogen levels are continuously high, 
deleterious mutations may accumulate 
over time (  9  ). 
  AID in autoimmunity  …   
  It is well-established that women are 
more prone to developing autoimmune 
diseases than men, but the reasons have 
largely remained unknown. These new 
fi  ndings by Pauklin et al. highlight an 
unexpected potential cause: estrogen-
stimulated AID protein may generate 
pathogenic antibodies with high affi   nity 
for self-proteins. However, the connec-
tion between antibodies and autoimmu-
nity is not always straightforward. For 
example, some autoimmune diseases are 
directly caused by self-reactive antibod-
ies, such as antibodies specifi  c for the 
acetylcholine receptor in myasthenia 
gravis. Other diseases, such as systemic 
sclerosis, are associated with elevated 
levels of autoantibodies, but no clear 
causative role has been established. 
Nonetheless, there is increasing evi-
dence to support a link between estro-
gen, autoimmunity, and AID (  Fig. 1  ). 
For example, estrogen levels are elevated 
in patients with systemic lupus erythe-
matosus (for review see reference [  10  ]). 
And in murine models, autoimmune B 
Why women are more susceptible to autoimmune diseases is not completely 
clear, but new data suggest that the hormone estrogen may play an impor-
tant role. A new study now shows that estrogen activates the expression of 
activation-induced deaminase (AID), a protein that drives antibody diversifi  -
cation by deaminating cytosine in DNA to uracil. If estrogen increases the 
level of AID, increased mutations could transform benign antibodies into 
anti-self pariahs. AID might also contribute to cancer  —  particularly in breast 
tissue, which is highly responsive to estrogen  —  by introducing mutations and 
strand breaks into the genome.
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show up-regulation of AID, such as gas-
trointestinal and hepatocellular cancers, 
which are associated with chronic in-
fl  ammation caused by long-term infec-
tions (i.e.,   Helicobacter pylori  ) (  16, 17  ) 
or tissue damage (liver cirrhosis) (  18  ). 
This chronic infl  ammation may result 
in aberrant AID expression through the 
NF-    B pathway, and increased AID 
could then introduce mutations into on-
cogenes such as p53 (  16  ). 
  Estrogen has previously been linked 
to various cancers, including breast, ovar-
ian, and endometrial cancer. Two diff  er-
ent mechanisms have been identifi  ed by 
which estrogen drives carcinogenesis (for 
review see reference [  19  ]). Metabolism 
of estrogen could produce mutagenic 
metabolites, or estrogen could bind to 
estrogen receptors, thereby altering the 
expression of various genes. If one of 
those genes is AID in breast tissue, the 
enzyme could target genes outside the Ig 
loci. For example,   BRCA1   and   BRCA2   
are tumor suppressor genes involved 
in DNA repair that are often mutated 
in breast and ovarian cancers. Thus, AID 
has the potential to wreak havoc on 
mechanisms devoted to maintaining ge-
nome stability. 
  Concluding remarks 
  The results presented by Pauklin et al. 
pose a new paradigm: increased estro-
gen levels produce higher levels of AID, 
which generates more mutations. This 
could be one explanation for the fi  nd-
ing that women have better immune 
responses and develop more autoim-
mune diseases than do men. The fi  nd-
ings also suggest that AID may play a 
role in cancer development in breast 
and ovarian tissues, although further 
work is needed to examine the delicate 
balance between estrogen and proges-
terone in regulating AID in vivo. If 
AID is involved in estrogen-driven dis-
eases, screening for AID expression in 
women with certain pathologies could 
potentially be combined with treat-
ments that regulate AID activity, per-
haps by inhibition of catalysis with small 
molecules. 
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cells have increased expression of AID 
with more antibody sequence diversity 
(  11  ); and loss of AID results in weakened 
autoimmune responses (  12  ). On the other 
hand, patients defi  cient for AID fre-
quently develop autoimmune disorders 
(  13  ), suggesting that unswitched, low-
affi   nity IgM antibodies can also bind to 
self-antigens. Thus, the presence or ab-
sence of AID seems to infl  uence autoim-
munity, but much more work is required 
to dissect the exact role of estrogen in 
this complex group of diseases. 
    …  and in cancer 
  AID is also associated with B cell can-
cers, but whether a gender bias exists in 
these diseases is not clear. Several forms 
of non-Hodgkin lymphoma have been 
linked to aberrant expression of AID. B 
cell  –  derived lymphomas and myelomas 
often result from altered CSR, in which 
oncogenes (i.e.,   MYC  ,   BCL1  ,   BCL2  , 
and   BCL6  ) are rearranged into switch 
regions containing AID-generated strand 
breaks (  14  ). The translocated genes then 
become dysregulated and oncogenesis 
occurs. Indeed, a recent study showed 
increased AID expression in peripheral 
blood samples taken fi  ve years before di-
agnosis of non-Hodgkin lymphoma 
(  15  ). Some other forms of cancer also 
  Figure 1.       Potential interactions between 
estrogen, AID, and disease.   Estrogen-driven 
transcription of AID may play a role in a variety 
of diseases, including certain types of autoim-
munity and cancer. It will be interesting to ex-
amine the role of estrogen in AID-associated 
cancers, for which no gender bias has yet been 
reported.   JEM VOL. 206, January 19, 2009  13
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